Key Findings
Body composition analyzers are the non-invasive, technologically advanced devices that are emphasized to measure and monitor body parameters while keeping a simple design and improving the ease of use. Moreover, they help to analyze cumulative disparities in body structure for a precise period.

The North America body composition analyzer market is estimated to grow from $XX million in 2018 to $XX million by 2027, at a CAGR of 10.91% between 2019 and 2027. North America accounted for nearly xx% of the global market share in 2018 and is expected to remain dominant throughout the forecast period. This is attributed to the presence of well-established healthcare infrastructure and continuous R&D initiatives related to the development of body composition analyzers.

Market Insights
A rise in prevalence of obesity drives the growth of the North American body composition analyzer market. Presence of large obese population base in the region leads to higher adoption of body composition analyzers. Obesity has long-term negative effects on health, including but not limited to heart disease, stroke, type 2 diabetes, high blood pressure, cancer, and other bone & joint diseases. Also, a rise in health awareness among Americans has led to an increase in sales of body composition analyzers in North America.

The United States and Canada market for body composition analyzer are the significant revenue contributors to the regional market. The increase in healthcare expenditure in the United States is single-handedly driving the body composition analyzer market during the forecast period.

Competitive Insights
The major market players that are profiled in the report are Tanita Corporation, Cosmed S.R.L., RJL Systems, Inc., Selvas AI Inc. (Jawon Medical Co., Ltd.), General Electric Company (GE Healthcare), SECA GmbH & Co. KG., InBody Co., Ltd., Jawon Medical Co., Ltd., Bodystat Ltd., Hologic, Inc., and Omron Corporation.